Multiple Sclerosis Spasticity: BMS-986368 Study

We are evaluating a new oral medication for spasticity in people with multiple sclerosis. The study aims to see if it improves symptoms and overall function compared to a placebo.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Carbomer 974p
Carbomer 974P is a polymer used to thicken, gel, and stabilize topical and oral formulations.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Cc-97489

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Fakultni Nemocnice U Sv Anny V Brne
I. neurologicka klinika
Brno, Czechia
Fakultni Nemocnice Hradec Kralove
Neurologicka klinika/MS centrum
Hradec Králové, Czechia
Nemocnice Pardubickeho kraje a.s.
Neurologie/MS centrum
Pardubice, Czechia

Sponsor: Celgene Corp.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.